AR059347A1 - Composiciones estabilizadas de proteinas que tienen un radical tiol libre - Google Patents

Composiciones estabilizadas de proteinas que tienen un radical tiol libre

Info

Publication number
AR059347A1
AR059347A1 ARP070100501A ARP070100501A AR059347A1 AR 059347 A1 AR059347 A1 AR 059347A1 AR P070100501 A ARP070100501 A AR P070100501A AR P070100501 A ARP070100501 A AR P070100501A AR 059347 A1 AR059347 A1 AR 059347A1
Authority
AR
Argentina
Prior art keywords
free
tiol
proteins
radical
stabilized compositions
Prior art date
Application number
ARP070100501A
Other languages
English (en)
Inventor
Gaozhong Zhu
Zahra Shahrokh
Kris Lowe
Vinh P Nguyen
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of AR059347A1 publication Critical patent/AR059347A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/04—Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones de proteínas que tienen tioles libres, y métodos para elaborar y utilizar tales composiciones. Reivindicacion 1: Una composicion que comprende una proteína que tiene un tiol libre y un carbohidrato, donde el carbohidrato está presente en una cantidad suficiente para mantener la estabilidad de la proteína y donde el pH de la composicion es menor de 7.
ARP070100501A 2006-02-07 2007-02-07 Composiciones estabilizadas de proteinas que tienen un radical tiol libre AR059347A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77155506P 2006-02-07 2006-02-07

Publications (1)

Publication Number Publication Date
AR059347A1 true AR059347A1 (es) 2008-03-26

Family

ID=38252288

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP070100501A AR059347A1 (es) 2006-02-07 2007-02-07 Composiciones estabilizadas de proteinas que tienen un radical tiol libre
ARP100104081A AR078885A2 (es) 2006-02-07 2010-11-04 Composiciones estabilizadas de proteinas que tienen un radical tiol libre. recipiente impermeable. metodo.
ARP170100522A AR107785A2 (es) 2006-02-07 2017-03-02 Composiciones estabilizadas de proteínas que tienen un radical tiol libre

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100104081A AR078885A2 (es) 2006-02-07 2010-11-04 Composiciones estabilizadas de proteinas que tienen un radical tiol libre. recipiente impermeable. metodo.
ARP170100522A AR107785A2 (es) 2006-02-07 2017-03-02 Composiciones estabilizadas de proteínas que tienen un radical tiol libre

Country Status (16)

Country Link
US (5) US7833766B2 (es)
EP (2) EP2361613B1 (es)
JP (8) JP5364382B2 (es)
AR (3) AR059347A1 (es)
AU (1) AU2007212021B2 (es)
CA (1) CA2641588C (es)
CY (1) CY1113199T1 (es)
DK (1) DK1986612T3 (es)
ES (1) ES2391657T3 (es)
HR (1) HRP20120994T1 (es)
PL (1) PL1986612T3 (es)
PT (1) PT1986612E (es)
RS (1) RS52459B (es)
SI (1) SI1986612T1 (es)
TW (1) TWI415630B (es)
WO (1) WO2007092829A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
PL1986612T3 (pl) * 2006-02-07 2013-02-28 Shire Human Genetic Therapies Stabilizowana kompozycja glukocerebrozydazy
AU2008292236A1 (en) * 2007-08-27 2009-03-05 Ablynx N.V. Needle-free delivery device for therapeutic proteins based on single antigen-binding domains such as NANOBODIES
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
TWI515006B (zh) * 2007-12-28 2016-01-01 巴克斯特國際公司 重組ｖｗｆ調配物
EP2244729B1 (en) * 2008-01-18 2016-11-02 MedImmune, LLC Cysteine engineered antibodies for site-specific conjugation
EP2113564A1 (en) * 2008-05-01 2009-11-04 Arecor Limited Protein formulation
WO2010021752A1 (en) * 2008-08-21 2010-02-25 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
NZ591940A (en) * 2008-10-10 2013-08-30 Alvine Pharmaceuticals Inc Dosage forms that facilitate rapid activation of zymogen
ES2409032T3 (es) * 2008-10-21 2013-06-24 Baxter International Inc. Formulaciones liofilizadas de vwf recombinante
SG175188A1 (en) * 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
CA3120503A1 (en) 2009-07-28 2011-02-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating gaucher disease
EP2325194A1 (en) 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
US9388452B2 (en) * 2010-04-08 2016-07-12 Baxalta Incorporated Methods for modeling protein stability
HUE029457T2 (en) 2010-11-11 2017-02-28 Abbvie Biotechnology Ltd Liquid formulations containing a high concentration of ANTI-TNF-alpha antibody
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
AU2013225816B2 (en) 2012-03-02 2017-10-26 Takeda Pharmaceutical Company Limited Compositions and methods for treating Type III Gaucher Disease
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
DK3177317T3 (en) 2014-08-04 2020-06-15 Csl Ltd Factor viii formulation
US9575064B2 (en) * 2014-09-02 2017-02-21 Perkinelmer Health Sciences, Inc. Methods relating to testing for lysosomal storage disorders
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
BR112022006698A2 (pt) * 2019-10-09 2022-09-06 Phoenix Eagle Company Pty Ltd Aprimoramento e estabilização da atividade proteolítica das proteases
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910822A (en) 1974-03-14 1975-10-07 Us Health Isolation of glucocerebrosidase from human placental tissue
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4925796A (en) 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5272066A (en) 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
WO1989005850A1 (en) 1987-12-23 1989-06-29 The United States Of America, As Represented By Th Cloned dna for synthesizing unique glucocerebrosidase
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
ATE138686T1 (de) 1988-12-23 1996-06-15 Genzyme Corp Cho-zellen befähigt enzymatisch aktive rekombinante-glukocerebrosidase zu produzieren
JPH03503721A (ja) 1988-12-23 1991-08-22 ジェンザイム　コーポレイション 酵素的に活性な組換えグルコセレブロシダーゼ
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US20020168750A1 (en) 1988-12-23 2002-11-14 James Rasmussen Enzymatically active recombinant glucocerebrosidase
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
DE69213714T2 (de) * 1991-01-21 1997-01-23 Genzyme Corp Herstellung enzymatischer aktiver glukocerebrosidase von rekombinanten zellen
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU5743994A (en) 1992-12-10 1994-07-04 Enzon, Inc. Glycolipid enzyme-polymer conjugates
AU6809494A (en) 1992-12-21 1994-07-19 Enzon, Inc. Purification of proteinaceous material
JP3002113B2 (ja) 1994-03-30 2000-01-24 寳酒造株式会社 糖質又は複合糖質の製造方法
DE69521074T2 (de) 1994-03-30 2001-09-13 Takara Shuzo Co Transglykosylierungsverfahren zur Herstellung eines Kohlenhydrats oder eines Glykokonjugates
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
AU693329B2 (en) 1995-04-13 1998-06-25 Corning Incorporated Dispersion managed optical waveguide
DK1516628T3 (da) * 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
CN1149088C (zh) * 1996-03-05 2004-05-12 奥奎斯特公司 骨生长促进组合物及其用途
AU732552B2 (en) 1996-07-15 2001-04-26 Genzyme Corporation Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
CA2265464C (en) 1996-09-13 2007-06-26 Transkaryotic Therapies, Inc. Therapy for .alpha.-galactosidase a deficiency
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
JPH10273500A (ja) 1997-03-03 1998-10-13 Noguchi Inst 複合糖ペプチド及びその製造法
JPH10306099A (ja) 1997-03-04 1998-11-17 Noguchi Inst 新規複合糖ペプチドおよびその製法
TW542721B (en) * 1997-08-06 2003-07-21 Melaleuca Inc Dietary supplements containing natural ingredients
DE69825288D1 (de) * 1997-08-07 2004-09-02 Univ Utah Prodrugs und konjugate von selenolenthaltenden verbindungen und ihre verwendung
US5939279A (en) 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
JP2001526239A (ja) * 1997-12-22 2001-12-18 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
GB9802249D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
GB9807464D0 (en) 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
EP0976838A1 (en) 1998-05-06 2000-02-02 Rhone-Poulenc Nutrition Animale Enzymes mixture
JPH11318441A (ja) 1998-05-14 1999-11-24 Nagase & Co Ltd 超耐熱耐酸性アミロプルラナーゼ
KR19990086271A (ko) 1998-05-27 1999-12-15 손경식 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
CA2330242A1 (fr) 1998-06-05 1999-12-16 Aventis Pharma S.A. Polypeptides possedant une activite de type beta-secretase
EP1137789B1 (en) 1998-12-09 2010-07-28 Phyton Holdings, LLC A method for manufacturing glycoproteins having human-type glycosylation
US6406455B1 (en) 1998-12-18 2002-06-18 Biovalve Technologies, Inc. Injection devices
GB9909066D0 (en) 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
AU5483600A (en) * 1999-06-11 2001-01-02 Jean A. Chmielewski Pharmaceutical materials and methods for their preparation and use
JP2003505430A (ja) * 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
AU2352201A (en) 1999-12-30 2001-07-16 Maxygen Aps Improved lysosomal enzymes and lysosomal enzyme activators
AU2001253181A1 (en) 2000-04-06 2001-10-23 Exegenics, Inc. Expression system for efficiently producing clinically effective lysosomal enzymes (glucocerebrosidase)
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
EP2554196B1 (en) 2000-11-30 2018-10-17 Valeritas, Inc. Fluid delivery and measurement systems
MXPA03006294A (es) 2001-01-18 2003-09-16 Merck Patent Gmbh Proteinas de fusion disfuncionales con actividad glucocerebrosidasa.
CN1156702C (zh) 2001-07-11 2004-07-07 上海晶泰生物技术有限公司 采用标记链霉亲和素-生物素技术的蛋白质芯片
US20030133924A1 (en) 2001-12-21 2003-07-17 Novazyme Pharmaceuticals, Inc. Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
CA2492143A1 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US7194924B2 (en) * 2002-07-31 2007-03-27 Lockheed Martin Corporation System and method for biohazard detection using compression
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
DK2857036T3 (en) * 2003-01-31 2017-03-13 Mount Sinai School Of Medicine Of New York Univ COMBINATION THERAPY FOR TREATMENT OF PROTEIN FAILURE DISORDERS
US20050265988A1 (en) 2004-03-18 2005-12-01 Byung-Kwon Choi Glycosylated glucocerebrosidase expression in fungal hosts
TW200606080A (en) * 2004-05-26 2006-02-16 Bristol Myers Squibb Co Container
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
CA2590590C (en) * 2004-12-22 2016-04-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
PL1986612T3 (pl) * 2006-02-07 2013-02-28 Shire Human Genetic Therapies Stabilizowana kompozycja glukocerebrozydazy
ATE511645T1 (de) 2006-03-17 2011-06-15 Biomarin Pharm Inc Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
US8905801B1 (en) 2007-12-31 2014-12-09 Brp Us Inc. Marine outboard motor
CA3120503A1 (en) 2009-07-28 2011-02-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating gaucher disease
WO2011107991A1 (en) 2010-03-02 2011-09-09 Protalix Ltd. Glucocerebrosidase multimers and uses thereof
JP5383591B2 (ja) 2010-05-24 2014-01-08 日立建機株式会社 建設機械の油圧駆動装置
EP2595651B1 (en) 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
JP5806015B2 (ja) 2011-06-30 2015-11-10 矢崎総業株式会社 電気接続箱

Also Published As

Publication number Publication date
AU2007212021A1 (en) 2007-08-16
EP2361613A1 (en) 2011-08-31
JP5364382B2 (ja) 2013-12-11
US20140219987A1 (en) 2014-08-07
JP2009526080A (ja) 2009-07-16
JP2015164960A (ja) 2015-09-17
EP2361613B1 (en) 2020-08-12
US9694057B2 (en) 2017-07-04
RS52459B (en) 2013-02-28
US8673298B2 (en) 2014-03-18
JP6894493B2 (ja) 2021-06-30
TWI415630B (zh) 2013-11-21
US7833766B2 (en) 2010-11-16
JP2016196512A (ja) 2016-11-24
JP6175102B2 (ja) 2017-08-02
CA2641588C (en) 2014-06-17
JP2021066752A (ja) 2021-04-30
JP2018035183A (ja) 2018-03-08
CA2641588A1 (en) 2007-08-16
WO2007092829A2 (en) 2007-08-16
US20070197439A1 (en) 2007-08-23
US20150283216A1 (en) 2015-10-08
TW200800296A (en) 2008-01-01
AR107785A2 (es) 2018-06-06
EP1986612B1 (en) 2012-09-12
JP5795295B2 (ja) 2015-10-14
ES2391657T3 (es) 2012-11-28
US9072785B2 (en) 2015-07-07
PL1986612T3 (pl) 2013-02-28
US20110091414A1 (en) 2011-04-21
SI1986612T1 (sl) 2013-01-31
JP2013010785A (ja) 2013-01-17
WO2007092829A3 (en) 2007-10-18
AU2007212021B2 (en) 2013-06-06
US20180104314A1 (en) 2018-04-19
JP2019116509A (ja) 2019-07-18
HRP20120994T1 (hr) 2012-12-31
AR078885A2 (es) 2011-12-07
CY1113199T1 (el) 2016-04-13
PT1986612E (pt) 2012-11-06
DK1986612T3 (da) 2012-10-29
EP1986612A2 (en) 2008-11-05
JP2020041000A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
AR059347A1 (es) Composiciones estabilizadas de proteinas que tienen un radical tiol libre
GT200900264A (es) Moléculas y métodos para modular la pro-proteina
BR112013023757A2 (pt) método para redução de viscosidade no processo de sacarificação
ECSP088159A (es) Formulaciones de inmunoconjugado
AR072165A1 (es) Composiciones para aclarar el color de la piel. aditivo aclarador de la piel. metodo.
BRPI0408373A (pt) composições para tratamento de pele que aumentam e reparam a função de barreira da pele
EA200970015A1 (ru) Волокнистые материалы и композиции
BR112018002196A8 (pt) formulação anti-ifnar1 estável
ES2622444T3 (es) Actividad trombopoyética de polipéptidos tirosil-ARNt sintetasa
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
PE20071111A1 (es) Metodos para modular el contenido de manosa de proteinas recombinantes
CR10528A (es) Proceso para producir poxvirus y composiciones de poxvirus
CO6290624A2 (es) Composición oral que contiene amino ácidos, fluoruro y un tampón, y método de preparación de la misma
RU2011113406A (ru) Композиции, включающие белок и катионный полимер и обладающие пониженной вязкостью
AR069657A1 (es) Composiciones activas antitranspirantes que tienen un cromatograma sec que exhibe alta intensidad de pico sec 4 y metodo para prepararlas
AR070356A1 (es) Producto para cuidado oral y metodos de uso del mismo
CL2011000209A1 (es) Composicion biocida que comprende ciprodinil y piribencarb; metodo para controlar enfermedades en plantas utiles o en material de propagacion causadas por fitopatogenos (div. sol. n° 2602-06).
BR112018011859A2 (pt) uso de composições tendo um conteúdo de 3,3´-metilenobis(2-metiloxazolidina) na remoção de compostos de enxofre a partir de correntes de processo
MEP10209A (en) Stable emulsion composition
BR112013033388A2 (pt) composição cimentícia e mistura
TW200738788A (en) Polyorganosiloxane composition for use in unsaturated elastomer, article made therefrom, and associated method
AR081324A1 (es) Produccion de composiciones unificadas de alta densidad
BRPI0508681A (pt) composição, método para branquear redutivamente uma suspensão mineral, e, produto
SV2009003222A (es) Composiciones de carbamato fenilalquilo ref. prd2745svpct
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación

Legal Events

Date Code Title Description
FC Refusal